Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience

by Mary A. Slatter, Kanchan Rao, Persis Amrolia, Terry Flood, Mario Abinun, Sophie Hambleton, Zohreh Nademi, Nick Goulden, Graham Davies, Waseem Qasim, Hubert

B. Gaspar, Andrew Cant, Andrew R. Gennery, and Paul Veys

BloodVolume 117(16):4367-4375

April 21, 2011

©2011 by American Society of Hematology

Kaplan-Meier survival curve.

Mary A. Slatter et al. Blood 2011;117:4367-4375

©2011 by American Society of Hematology

Split cell chimerism in patients more than 1 year after HSCT. Of 42 patients, 24 (57%) had 100% donor chimerism in all cell lines: 15 of 26 (58%) in the fludarabine group and 9 of 16 (56%) in the

cyclophosphamide group.

Mary A. Slatter et al. Blood 2011;117:4367-4375

©2011 by American Society of Hematology

Split cell chimerism in 42 patients more than 1 year after HSCT by disease.

Mary A. Slatter et al. Blood 2011;117:4367-4375

©2011 by American Society of Hematology

Split cell chimerism in MSD/MFD recipients more than 1 year after HSCT. Numbers are small (7 in fludarabine group and 5 in cyclophosphamide group), but there is a suggestion that chimerism is

better after fludarabine in all cell lineages.

Mary A. Slatter et al. Blood 2011;117:4367-4375

©2011 by American Society of Hematology

Split cell chimerism in unrelated donor recipients more than 1 year after HSCT according to stem cell source.

Mary A. Slatter et al. Blood 2011;117:4367-4375

©2011 by American Society of Hematology